Unpredictable episodes of paroxysmal supraventricular tachycardia (PSVT) often have a negative impact on patient quality of life by causing uncomfortable, disconcerting symptoms during episodes (e.g., palpitations, chest pain, dizziness, syncope, shortness of breath, anxiety), by imposing restrictions on patient activities, and by potential association with medication-related side effects. Among commercially insured patients, healthcare spending increases substantially following diagnosis of PSVT, and more than two-thirds of that increased spending is for services related to PSVT and other cardiac rhythm disorders. These spending increases are seen for both outpatient and inpatient services; in particular, emergency department (ED) visits and hospitalizations both increase in the year following diagnosis, and then look-back analysis typically confirms that ED utilization is also high in the year prior to diagnosis, potentially reflecting difficulties with diagnosis. Current treatment approaches for PSVT are associated with a large burden on providers and carry a high economic burden for payers; just as importantly, however, they create a sense of powerlessness among many patients that often cannot be addressed with a reliable self-treatment strategy. New approaches are warranted to improve diagnosis, management, quality of life, and sense of well-being among patients with PSVT.
AcademicCME has developed a 1-hour program addressing the epidemiology, disease burden, definitive diagnosis, and current therapy of acute episodes of PSVT, along with information about an ongoing phase 3 trial that will evaluate the safety and efficacy of an on-demand, patient-actuated treatment for PSVT.
Interventional and clinical cardiologists, cardiothoracic and trauma surgeons, and emergency medicine/critical care specialists, as well as other clinicians, including nurses, NPs, PAs, and pharmacists who are involved in the management of patients with PSVT
- Review the symptom burden, epidemiologic, and pharmacoeconomic basis of current abortive strategies for PSVT
- Analyze and understand the different perspectives of various healthcare providers on optimizing PSVT management
- Discuss workflow, collaboration, and management strategies for clinical trial execution in the current pandemic-impacted era of practice
- Review in detail the rationale and methodology of a Phase 3 clinical trial that identifies patients with PSVT suitable for patient-actuated treatment, and follow its execution as the scientific, clinical, and outcomes-driven environment of PSVT management evolves
I. PSVT: Disease Burden
II. Clinical Perspectives on Current and Emerging Pharmacologic Therapies for PSVT
III. Rationale and Methodology of a Phase 3 Placebo-Controlled Trial of a New, Patient -Actuated Therapy for PSVT
- The NODE-301 and RAPID Phase 3 Trials
IV.Challenges in Executing Clinical Trials in the Acute Care Environment During COVID
V. Expert Panel Discussion
Disclosures of Conflict of Interest
It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
|Faculty||Relationship Identified With:|
|Charles V. Pollack Jr., MD (Course Chair)||Consultant/Advisor: AstraZeneca Pharmaceuticals; PhaseBio Pharmaceuticals, Inc.; Milestone Pharmaceuticals, Inc.
Grant/Research Support: AstraZeneca Pharmaceuticals
|Paul Dorian, MD||Consultant/Advisor: Milestone Pharmaceuticals, Inc.|
|Bruce Stambler, MD||Consultant/Advisor: Milestone Pharmaceuticals, Inc.|
Planners and Peer Reviewers
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Joseph Feick, PharmD; Gabrielle Fiorelli, CRNP and Nicole McMenamin hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. This activity was planned by and for the healthcare team.
Through an agreement between the American Medical Association and the European Union of Medical Specialists, physicians may convert AMA PRA Category 1 Credit™ to an equivalent number of European CME Credits® (ECMECs®). These credits will be recognized by all National Accreditation Authorities in Europe with which the UEMS has a signed agreement of recognition of credits.
The Royal College and Physicians and Surgeons of Canada recognizes credits offered by the ACCME through the International Academy for CPD Accreditation agreement.
Credit Designation Statements
AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit TM.
AcademicCME designates this live material for a maximum of 1.0 CNE Contact Hour (Provider Number P0491).
AcademicCME designates this continuing education activity for 1.0 CPE Contact Hour (0.10 CEU) of continuing pharmacy education credit (UAN #: JA4008190-0000-21-013-H04-P).
Participants should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been supported by an independent educational grant from Milestone Pharmaceuticals, Inc.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Milestone Pharmaceuticals, Inc. do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
In order to claim credit, participants must complete the following:
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
- Complete the Pre-Activity Questions
- Read or Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- Learners who receive a grade of 70% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
- CPE credit will be posted to the learner’s CPE Monitor profile within 60 days of completion.
- CME and CNE credit will be issued appropriate certificate of completion.
- Others may request a “certificate of completion”.
- Learners should claim only the credit commensurate with the extent of their participation in the activity.
CE Inquiries/Special Needs
For all CE inquiries or special needs, please contact [email protected].